Valentina Vanini

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Mycobacterium tuberculosis diversity and macrophage heterogeneity dictate phagosomal acidification.

Mycobacterium tuberculosis diversity and macrophage heterogeneity dictate phagosomal acidification.

Journal: Microbiology spectrum

Published: July 20, 2026

Type 2 Diabetes Reshapes the B-Cell Compartment in Tuberculosis, with Reduction of Transitional B Cells and Expansion of Plasmablasts.

Type 2 Diabetes Reshapes the B-Cell Compartment in Tuberculosis, with Reduction of Transitional B Cells and Expansion of Plasmablasts.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: June 27, 2026

IRGM genetic variants associate with tuberculosis disease in a European population.

IRGM genetic variants associate with tuberculosis disease in a European population.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: May 20, 2026

Peptide MegaPools Approach to Evaluate the Dengue-Specific CD4 and CD8 T-Cell Response.

Peptide MegaPools Approach to Evaluate the Dengue-Specific CD4 and CD8 T-Cell Response.

Journal: Pathogens (Basel, Switzerland)

Published: October 28, 2025

3-Gene-TB-SCORE Accuracy for Tuberculosis Disease Diagnosis Is Not Affected by Immune-Mediated Inflammatory Disease Comorbidity.

3-Gene-TB-SCORE Accuracy for Tuberculosis Disease Diagnosis Is Not Affected by Immune-Mediated Inflammatory Disease Comorbidity.

Journal: International journal of molecular sciences

Published: September 03, 2025

Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies.

Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies.

Journal: Frontiers in immunology

Published: August 08, 2025

Characterization of QuantiFERON-TB-Plus Results in Patients with Tuberculosis Infection and Multiple Sclerosis.

Characterization of QuantiFERON-TB-Plus Results in Patients with Tuberculosis Infection and Multiple Sclerosis.

Journal: Neurology international

Published: June 24, 2025

Anti-SARS-CoV-2 B and T-Cell Immune Responses Persist 12 Months After mRNA Vaccination with BNT162b2 in Systemic Lupus Erythematosus Patients Independently of Immunosuppressive Therapies.

Anti-SARS-CoV-2 B and T-Cell Immune Responses Persist 12 Months After mRNA Vaccination with BNT162b2 in Systemic Lupus Erythematosus Patients Independently of Immunosuppressive Therapies.

Journal: Vaccines

Published: March 11, 2025

Specific immune response to M. tuberculosis and ability to in vitro control mycobacterial replication are not impaired in subjects with immune-mediated inflammatory disease and tuberculosis infection.

Specific immune response to M. tuberculosis and ability to in vitro control mycobacterial replication are not impaired in subjects with immune-mediated inflammatory disease and tuberculosis infection.

Journal: Frontiers in immunology

Published: August 21, 2024

Therapy modulates the response to T cell epitopes over the spectrum of tuberculosis infection.

Therapy modulates the response to T cell epitopes over the spectrum of tuberculosis infection.

Journal: The Journal of infection

Published: August 05, 2024

Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination.

Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination.

Journal: Vaccines

Published: July 08, 2024

Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosis.

Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosis.

Journal: Frontiers in immunology

Published: April 03, 2024

Showing 1-12 of 67

Last Updated: 09/26/2026